Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BURLINGTON, Mass., March 01, 2016 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in two investor conferences in March.
David Roberts, President, is scheduled to present at the 28th Annual ROTH Conference at the Ritz-Carlton, Laguna Niguel, CA on Tuesday, March 15, 2016. The company presentation is scheduled to begin at 12:00 pm PDT.
JJ Pellegrino, CFO, is scheduled to present at the Sidoti Emerging Growth Conference at the Marriott Marquis, New York City on Thursday, March 31, 2016.
For more information or to register, please visit the conference websites at www.roth.com and www.sidoti.com.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
Contact: LeMaitre Vascular, Inc. Sandra Millar +1-781-425-1686 [email protected] http://www.lemaitre.com
